Akebia Therapeut Stock Price, News & Analysis

Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company dedicated to improving the lives of individuals affected by kidney disease, will participate in the 39th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 13, 2021, at 2:50 p.m. EST, led by John P. Butler, President and CEO. Interested parties can access the live webcast and replay on the Investors section of Akebia's website. Founded in 2007 and based in Cambridge, Massachusetts, Akebia is focused on developing therapeutics for kidney disease.

Akebia Therapeutics (Nasdaq: AKBA) announced a virtual panel scheduled for December 16, 2020, aimed at discussing hyperphosphatemia management in patients with chronic kidney disease (CKD) on dialysis. The panel will feature insights from kidney care professionals and emphasize the importance of a multidisciplinary care approach and telehealth monitoring. Akebia's AURYXIA^® (ferric citrate) is FDA-approved for controlling serum phosphorus levels in CKD patients on dialysis and treating iron deficiency anemia in CKD patients not on dialysis.

Akebia Therapeutics (Nasdaq: AKBA) announced the granting of stock options to 7 newly-hired employees on November 30, 2020. The options, totaling 49,000 shares, have an exercise price of $3.31 per share, equivalent to the stock's closing price on the grant date. These options will vest over four years, with 25% vesting after one year and the remainder quarterly, contingent on continued employment. This move adheres to Nasdaq Listing Rule 5635(c)(4) and aims to incentivize the new hires.

Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease treatments, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 3, 2020. The company’s President, John P. Butler, and CFO, David A. Spellman, will engage in virtual meetings. A recording of their presentation will be accessible on the conference site and Akebia's investor page from November 24 to December 3, 2020. Akebia, founded in 2007 and based in Cambridge, Massachusetts, aims to enhance the quality of life for those affected by kidney disease.

Akebia Therapeutics (Nasdaq: AKBA) has been ranked 10th on Deloitte's Technology Fast 500, reflecting a staggering revenue growth of 21,724% from 2016 to 2019. This rapid growth is attributed to the strategic merger with Keryx Biopharmaceuticals on December 12, 2018, which enabled revenue from the commercial product AURYXIA®. Additionally, Akebia's collaboration revenue from the development of vadadustat, an investigational treatment for anemia due to chronic kidney disease, further supports this growth. The company is recognized for its commitment to improving the lives of kidney disease patients.

Akebia Therapeutics (AKBA) announced the publication of a manuscript in Nephrology Dialysis Transplantation, detailing the study design and methodology of its Phase 3 INNO₂VATE program. This research evaluates vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treating anemia due to chronic kidney disease. The manuscript highlights that demographics of study participants align with typical dialysis-dependent CKD patients, suggesting broad applicability of results. Vadadustat met both primary and key secondary efficacy and safety endpoints compared to darbepoetin alfa.

Akebia Therapeutics (Nasdaq: AKBA) announced its Q3 2020 financial results, reporting total revenue of $60 million, down from $92 million in Q3 2019, primarily due to decreased collaboration revenue. Despite a 14.6% increase in net product revenue for Auryxia® to $34.4 million, net loss widened to $60 million from $54.6 million. Akebia completed a pre-NDA meeting with the FDA for vadadustat, an oral treatment for anemia due to chronic kidney disease, targeting a $2 billion market. The company aims to submit an NDA in early 2021.

On November 3, 2020, Akebia Therapeutics (Nasdaq: AKBA) announced it granted stock options to 6 newly-hired employees, totaling 27,000 shares. The options, priced at $2.22 per share, reflect the company's closing stock price on the grant date of October 30, 2020. Each option vests over four years, with 25% vesting on the first anniversary and the remainder quarterly, conditional on continued employment. These grants align with Nasdaq Listing Rule 5635(c)(4), enhancing the company’s talent acquisition strategy.

Akebia Therapeutics (Nasdaq: AKBA) announced it will release its third-quarter financial results for the period ending September 30, 2020, on November 5, 2020, before market opening. A conference call to discuss these results and business updates will take place at 9:00 a.m. ET on the same day, accessible via phone and webcast. The call will be archived online for later access. Akebia is committed to improving the lives of those with kidney disease and has been operational since 2007, headquartered in Cambridge, Massachusetts.